Poolbeg Pharma (LON:POLB) Scientific Advisor Dr Paula Maguire outlines her experience and what she’s so excited about with Poolbeg.
Poolbeg Pharma fosters data-driven innovation and the most advanced scientific practices in the research & development. It’s a leading biopharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model.
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that further to its announcement on 19 September 2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’) relating to the challenge
Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure to improve R&D productivity and efficiency. Artificial intelligence
Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The Japanese Patent Office has issued a notice of
Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma and CytoReason. Speakers: Jeremy Skillington – CEO of
Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. The
Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is to be
Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development, within the
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2023. Interim Results Highlights and Business Update · Strong cash balance
Climate change stands as one of the most pressing challenges of our time, affecting various aspects of our planet and human existence. Amid discussions about its environmental consequences, we often overlook the significant connection between climate change and
By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ which prevents pathogens infecting the body by producing a protective response in the areas of the body where there is a high level of infectious threat,
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
Warnings about the potential threats of artificial intelligence (AI) technology have been coming from various industries. However, one of Britain’s largest drug firms, GlaxoSmithKline (GSK), believes that the use of cutting-edge AI could have a positive impact on
Artificial intelligence is everywhere. According to GlobalData forecasts, every segment of the AI market is expected to grow in the coming decade and it will be worth around $909 billion by 2030. As a result, new uses are
Warnings about the potential threats of artificial intelligence (AI) technology have been coming thick and fast from a wide range of industries. But the use of cutting-edge AI could benefit us all by dramatically speeding up the development
The field of drug discovery is challenging and time-consuming, but generative artificial intelligence (AI) has the potential to revolutionize this process. Generative AI, a subfield of AI, focuses on creating new data instances that resemble existing data. In
The emergence of AI, notably in the field of drug discovery, is reshaping the future of medicine The emergence of artificial intelligence (AI), notably in the field of drug discovery, is reshaping the future of medicine. The pharmaceutical business is
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.